Creative Planning Has $1.01 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Creative Planning increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 52.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,808 shares of the company’s stock after acquiring an additional 6,811 shares during the period. Creative Planning’s holdings in Crinetics Pharmaceuticals were worth $1,012,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Russell Investments Group Ltd. lifted its position in Crinetics Pharmaceuticals by 366,571.4% during the 1st quarter. Russell Investments Group Ltd. now owns 51,334 shares of the company’s stock worth $2,403,000 after buying an additional 51,320 shares in the last quarter. Swiss National Bank increased its holdings in Crinetics Pharmaceuticals by 21.4% during the first quarter. Swiss National Bank now owns 126,500 shares of the company’s stock worth $5,921,000 after buying an additional 22,300 shares during the last quarter. Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals by 2.1% during the first quarter. Vanguard Group Inc. now owns 3,575,076 shares of the company’s stock worth $167,349,000 after purchasing an additional 72,624 shares during the period. SG Americas Securities LLC lifted its holdings in Crinetics Pharmaceuticals by 1,224.8% during the 2nd quarter. SG Americas Securities LLC now owns 79,051 shares of the company’s stock valued at $3,541,000 after purchasing an additional 73,084 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Crinetics Pharmaceuticals by 27.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,823,218 shares of the company’s stock valued at $178,966,000 after acquiring an additional 814,360 shares during the period. 98.51% of the stock is owned by institutional investors and hedge funds.

Crinetics Pharmaceuticals Trading Up 0.4 %

CRNX stock opened at $55.96 on Friday. The stock’s fifty day simple moving average is $53.65 and its two-hundred day simple moving average is $50.03. The stock has a market cap of $4.41 billion, a P/E ratio of -14.85 and a beta of 0.63. Crinetics Pharmaceuticals, Inc. has a 1-year low of $25.75 and a 1-year high of $60.04.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its earnings results on Thursday, August 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.08). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.47 million. Crinetics Pharmaceuticals’s revenue was down 59.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.94) earnings per share. As a group, analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, insider Stephen F. Betz sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $53.19, for a total value of $159,570.00. Following the completion of the transaction, the insider now directly owns 69,611 shares in the company, valued at approximately $3,702,609.09. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Crinetics Pharmaceuticals news, insider Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total transaction of $785,306.25. Following the transaction, the insider now directly owns 28,507 shares of the company’s stock, valued at approximately $1,557,337.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen F. Betz sold 3,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $53.19, for a total transaction of $159,570.00. Following the completion of the sale, the insider now directly owns 69,611 shares of the company’s stock, valued at $3,702,609.09. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 43,410 shares of company stock valued at $2,275,929 in the last 90 days. 6.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on CRNX shares. JMP Securities reaffirmed a “market outperform” rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a research report on Friday, September 27th. Oppenheimer reaffirmed an “outperform” rating and set a $73.00 price target (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 price target on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th. JPMorgan Chase & Co. increased their price target on Crinetics Pharmaceuticals from $47.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Finally, HC Wainwright raised their price objective on Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Crinetics Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $68.55.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.